Showing results (41-50 of 100) with videos related to

Sort By:
Pageof 10
Respiratory Research|May 14, 2021
Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: results of a multicenter, randomized, double-blind, parallel-group controlled trialZe-Guang Zheng, Wu-Zhuang Sun, Jie-Ying Hu, et al.
Journal of Cancer|July 21, 2018
The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene PanelWu Zhuang, Junxun Ma, Xudong Chen, et al.
Journal of Hepatocellular Carcinoma|December 11, 2023
Clinical Complete Response After Conversion Therapy for Unresectable Hepatocellular Carcinoma: Is Salvage Hepatectomy Necessary?Jia-Yi Wu, Jun-Yi Wu, De-Yi Liu, et al.
Cancer Biology & Medicine|March 12, 2021
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trialTianqing Chu, Jun Lu, Minghong Bi, et al.
Journal of Neuro-Oncology|November 23, 2023
Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysisYaping Hong, Qian Miao, Xinlong Zheng, et al.
Liver Cancer|August 20, 2025
Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple TherapyJun-Yi Wu, Zhen-Xin Zeng, Yi-Nan Li, et al.
Cancer Medicine|November 7, 2019
Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center studyLei Lei, Wen-Xian Wang, You-Cai Zhu, et al.
Cancer Science|December 13, 2019
Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center studyLei Lei, Wen-Xian Wang, You-Cai Zhu, et al.
Liver Cancer|October 22, 2024
Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion SurgeryZhen-Xin Zeng, Jia-Yi Wu, Jun-Yi Wu, et al.
BMJ (Clinical Research Ed.)|June 5, 2025
Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trialWenfeng Fang, Xingya Li, Qiming Wang, et al.
Pageof 10